Inmune Bio Inc.
INMB· Nasdaq
Released Aug 7, 2023, after the close
10-Q filed Aug 7, 2023, 38 days after period end · 0001213900-23-064057
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $46.00K | $16.00K | $0.00 | — |
| Net Income | -$6.50M | -$6.84M | -$6.66M | -$2.11M |
| EPS Diluted | -$0.36 |
Inmune Bio Inc. · CIK 1711754 · Engraved from SEC EDGAR
| -$0.38 |
| -$0.44 |
| -$0.20 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.